XBIO vs. PFE

In the year-to-date period, XBIO achieves a -24.56% return, which is significantly lower than PFE's -11.75% return. Over the past 10 years, XBIO has underperformed PFE with an annualized return of -44.28%, while PFE has yielded a comparatively higher 0.58% annualized return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Xenetic Biosciences, Inc. (XBIO) and Pfizer Inc. (PFE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current XBIO Sharpe Ratio is -0.35, which is higher than the PFE Sharpe Ratio of -0.67. The chart below compares the historical Sharpe Ratios of XBIO and PFE, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

XBIO has not paid dividends to shareholders, while PFE's dividend yield for the trailing twelve months is around 7.52%.

The maximum XBIO drawdown since its inception was -99.94%, which is greater than PFE's maximum drawdown of -58.96%. Use the drawdown chart below to compare losses from any high point for XBIO and PFE. For additional features, visit the drawdowns tool.

Xenetic Biosciences, Inc. (XBIO) has a higher volatility of 13.84% compared to Pfizer Inc. (PFE) at 9.76%. This indicates that XBIO's price experiences larger fluctuations and is considered to be riskier than PFE based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Xenetic Biosciences, Inc. and Pfizer Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.